Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market Perform

September 19, 2016 1:29 PM EDT
Get Alerts SRPT Hot Sheet
Price: $61.41 +0.71%

Rating Summary:
    16 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 9 | New: 77
Trade SRPT Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Underperform to Market Perform with a price target of $50.00 (from $5.00).

Analyst Joseph Schwartz commented, "Sarepta's eteplirsen (Exondys 51, Duchenne Muscular Dystrophy) surprisingly received FDA's accelerated approval (AA), in stark contrast to the FDA's negative commentary throughout the entire review including the AdCom and recent PROMOVI dystrophin analysis. This decision is extremely unprecedented and follows major disputes among Agency personnel regarding their interpretations of very limited clinical/biomarker data. Ultimately, it appears to us that the FDA bowed to external pressure from patient advocates and others who demanded that a safe and potentially efficacious drug be made available. We are raising our rating to MP (from UP) and PT to $50 (from $5)."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst PT Change, Upgrades

Related Entities

AdCom

Add Your Comment